Tempus AI leverages AI for treatment decisions and diagnostics, thriving in the booming healthcare AI market with strong ...

Tempus AI's financials have significantly improved, with positive cash flow expected next quarter. Read why TEM stock is a ...

Tempus AI stock surged 40% YTD, driven by acquisitions and investor confidence in healthcare AI. Can its momentum spark ...

Acquisition: Closed the acquisition of Ambry Genetics on February 3. Google Agreement: Extended for another five years. Tempus AI Inc (NASDAQ:TEM) reported a 35.8% year-over-year revenue growth in ...

The acquisition of Ambry Genetics, finalized in February 2025, further strengthens Tempus’ genomics capabilities by adding a West Coast lab and expanding inherited risk testing. Another ...

The market's appetite for AI applications in healthcare is rapidly increasing, with TEM emerging as a top contender in this ...

Acquisition: Closed the acquisition of Ambry Genetics on February 3. Google Agreement: Extended for another five years. Tempus AI Inc (NASDAQ:TEM) reported a 35.8% year-over-year revenue growth in Q4 ...

Key Points About Article Just a few weeks ago, Tempus AI (NASDAQ: TEM) rocketed from about 44% higher. All on news it just acquired Ambry Genetics and on news, Nancy Pelosi took a stake in the TEM ...

Tempus AI has projected revenue of $1.24 billion and an expected adjusted EBITDA of $5 million. The company anticipates growth in its core business and the recently acquired Ambry Genetics ...